Skip to main content
Premium Trial:

Request an Annual Quote

Compugen and Biosite Expand Dx-Development Alliance

NEW YORK (GenomeWeb News) — Biosite will have access to more of Compugen’s diagnostic and immunoassay biomarkers under a renewed and expanded partnership and licensing agreement, Compugen said today.
 
In June 2005 the companies penned an alliance to develop and commercialize immunoassay-based diagnostics for cardiovascular and oncology indications based on several of Compugen’s gene targets.
 
Under the new agreement, which covers the same indications, Compugen will receive milestone payments and royalties from product sales that resulted from its contribution.
 
Compugen also said it will hold the rights to therapeutic applications of targets and antibodies associated with them.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.